My NCBISign In

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 46

    1.

    Error occurred: cannot get document summary

    PMID:
    22287783

    2.

    Error occurred: cannot get document summary

    PMID:
    22287782

    3.

    Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.

    Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.

    Anticancer Res. 2012 Feb;32(2):633-41.

    PMID:
    22287756
    [PubMed - indexed for MEDLINE]

    Related citations

    4.

    Error occurred: cannot get document summary

    PMID:
    22296454

    5.

    Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer.

    Loeb S, Metter EJ, Kan D, Roehl KA, Catalona WJ.

    BJU Int. 2012 Feb;109(4):508-13; discussion 513-4. doi: 10.1111/j.1464-410X.2011.10900.x. Epub 2012 Feb 1.

    PMID:
    22296334
    [PubMed - indexed for MEDLINE]

    Related citations

    6.

    Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

    Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

    BJU Int. 2012 Jan 30. doi: 10.1111/j.1464-410X.2011.10875.x. [Epub ahead of print]

    PMID:
    22289613
    [PubMed - as supplied by publisher]

    Related citations

    7.

    Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.

    van Leeuwen PJ, Otto SJ, Kranse R, Roobol MJ, Bul M, Zhu X, de Koning H, Schröder FH.

    BJU Int. 2012 Jan 30. doi: 10.1111/j.1464-410X.2011.10811.x. [Epub ahead of print]

    PMID:
    22288823
    [PubMed - as supplied by publisher]

    Related citations

    8.

    The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.

    Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA.

    BJU Int. 2012 Jan;109(1):32-9. doi: 10.1111/j.1464-410X.2011.10422.x. Epub 2011 Jul 20.

    PMID:
    21777360
    [PubMed - indexed for MEDLINE]

    Related citations

    9.

    Postoperative systems models more accurately predict risk of significant disease progression than standard risk groups and a 10-year postoperative nomogram: potential impact on the receipt of adjuvant therapy after surgery.

    Donovan MJ, Khan FM, Powell D, Bayer-Zubek V, Cordon-Cardo C, Costa J, Eastham J, Scardino P.

    BJU Int. 2012 Jan;109(1):40-5. doi: 10.1111/j.1464-410X.2011.10398.x. Epub 2011 Jul 19.

    PMID:
    21771247
    [PubMed - indexed for MEDLINE]

    Related citations

    10.

    Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer : A Prostate Cancer Clinical Trials Consortium trial.

    Ross RW, Galsky MD, Febbo P, Barry M, Richie JP, Xie W, Fennessy FM, Bhatt RS, Hayes J, Choueiri TK, Tempany CM, Kantoff PW, Taplin ME, Oh WK.

    Cancer. 2012 Jan 26. doi: 10.1002/cncr.27416. [Epub ahead of print]

    PMID:
    22282219
    [PubMed - as supplied by publisher]

    Related citations

    11.

    Copy number alterations of c-MYC and PTEN are prognostic factors for relapse after prostate cancer radiotherapy.

    Zafarana G, Ishkanian AS, Malloff CA, Locke JA, Sykes J, Thoms J, Lam WL, Squire JA, Yoshimoto M, Ramnarine VR, Meng A, Ahmed O, Jurisca I, Milosevic M, Pintilie M, van der Kwast T, Bristow RG.

    Cancer. 2012 Jan 26. doi: 10.1002/cncr.26729. [Epub ahead of print]

    PMID:
    22281794
    [PubMed - as supplied by publisher]

    Related citations

    12.

    PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

    Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML.

    Cancer Res. 2012 Mar 15;72(6):1529-37. Epub 2012 Jan 26.

    PMID:
    22282656
    [PubMed - indexed for MEDLINE]

    Related citations

    13.

    Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

    Wan X, Liu J, Lu JF, Tzelepi V, Yang J, Starbuck MW, Diao L, Wang J, Efstathiou E, Vazquez ES, Troncoso P, Maity SN, Navone NM.

    Clin Cancer Res. 2012 Feb 1;18(3):726-36.

    PMID:
    22298898
    [PubMed - indexed for MEDLINE]

    Related citations

    14.

    Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer.

    Coss CC, Jones A, Parke DN, Narayanan R, Barrett CM, Kearbey JD, Veverka KA, Miller DD, Morton RA, Steiner MS, Dalton JT.

    Endocrinology. 2012 Mar;153(3):1070-81. Epub 2012 Jan 31.

    PMID:
    22294742
    [PubMed - indexed for MEDLINE]

    Related citations

    15.

    Re: Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the reduction by dutasteride of prostate cancer events trial.

    Oelke M.

    Eur Urol. 2012 Mar;61(3):624-5. No abstract available.

    PMID:
    22289977
    [PubMed]

    Related citations

    16.

    Re: A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.

    Moyad MA.

    Eur Urol. 2012 Mar;61(3):623-4. No abstract available.

    PMID:
    22289976
    [PubMed]

    Related citations

    17.

    Re: Prediction of erectile function following treatment for prostate cancer.

    Schellhammer P.

    Eur Urol. 2012 Mar;61(3):622. No abstract available.

    PMID:
    22289975
    [PubMed]

    Related citations

    18.

    Re: Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection.

    Delongchamps NB, Zerbib M.

    Eur Urol. 2012 Mar;61(3):622-3. No abstract available.

    PMID:
    22289974
    [PubMed]

    Related citations

    19.

    Comment on the US Preventive Services Task Force's draft recommendation on screening for prostate cancer.

    Kwiatkowski M, Klotz L, Hugosson J, Recker F.

    Eur Urol. 2012 Apr;61(4):851-4. Epub 2012 Jan 24. No abstract available.

    PMID:
    22285762
    [PubMed - in process]

    Related citations

    20.

    Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature.

    Chade DC, Eastham J, Graefen M, Hu JC, Karnes RJ, Klotz L, Montorsi F, van Poppel H, Scardino PT, Shariat SF.

    Eur Urol. 2012 May;61(5):961-71. Epub 2012 Jan 23.

    PMID:
    22280856
    [PubMed - in process]

    Related citations

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Filters: Manage Filters

      Find related data

      Recent activity

      Clear Turn Off Turn On

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      You are here: NCBI > Literature > PubMed
      Write to the Help Desk